NEWS & INSIGHTS

Inside Cure51

Learn about our journey through company milestones, research progress, partnerships and insider insights, and meet the people turning an ambitious idea into a growing global cancer research techbio.

Milestones | Insights | The people behind the research

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

Aug 26, 2026

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

Cure51's product ecosystem connects multi-omics data, AI and scientific workflows to accelerate cancer target discovery

Jul 22, 2026

Our Patient Committee is a key part of our scientific approach

We work closely with exceptional survivors, clinicians, researchers and patient advocates across our international network

Jun 16, 2026

until-all-survive-website-for-cancer-patients

UntilAllSurvive.com: we're launching a new website for cancer patients!

UntilAllSurvive.com: a new website for cancer patients!

Jul 2, 2026

Emna Makhlouf, Chief of Staff: "Working with cancer survivors gives a lot of purpose to what we do"

Emna Makhlouf, Chief of Staff, shares why our scientific approach feels positive

May 5, 2026

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

A fundamental shift: precision medicine is becoming actionable

Apr 21, 2026

New walls, same mission: we have a new home!

Apr 28, 2026

cure51-servier-paris-saclay-pscc-annual-event

Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

Biotech startups and pharmaceutical companies can strengthen partnerships to accelerate drug development

Apr 7, 2026

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Running an international oncology network across 50+ countries requires rigorous coordination and strict clinical research compliance

Mar 25, 2026

Advancing Cancer Research Through Patient Advocacy

Working hand in hand with patient advocates to advance Pancreatic Cancer Research

Mar 18, 2026

Cure51's CEO Nicolas Wolikow: How does AI help advance our Rosalind Study?

Mar 3, 2026

Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

Feb 24, 2026

ROSALIND